Analytical (technologies & services)

ATMPS and Assurea team up to ensure audit readiness for cell and gene therapy innovators

04-Jan-2022 By Jane Byrne

ATMPS Ltd, a UK developer of blockchain-based cell orchestration platforms for advanced therapies is collaborating with US quality and compliance consultancy, Assurea LLC, to develop a fully complaint blockchain approach for end-to-end supply chain management...

G42 and Mubadala to establish biopharma manufacturing campus in Abu Dhabi

03-Jan-2022 By Jane Byrne

Abu Dhabi-based entities, the sovereign wealth fund, Mubadala Investment Company, and AI and cloud computing specialist, G42, are to set up a biopharma campus there; the move is aimed at bolstering biopharma linked innovation, R&D and manufacturing...

Deloitte: Artificial intelligence technology investments prove top priority for biopharma leaders

22-Dec-2021 By Jane Byrne

The pandemic has focused biopharma industry minds on digital innovation, finds a Deloitte report.

NPD Gallery: Technology insider

21-Dec-2021 By Jane Byrne

What's new in biopharmaceutical manufacturing components and technology? We take a look.

Aussie rules: 'Game-changing' 3D cell culture developer looks to expand US footprint, raises $25m

16-Dec-2021 By Jane Byrne

Australia company, Inventia Life Science, which is focused on advanced 3D cell cultures for research and clinical purposes, has just closed a US$25M Series B funding round, led by Blackbird Ventures.

SGS acquires live biotherapeutics focused CDMO

14-Dec-2021 By Jane Byrne

SGS, the Swiss-based testing, inspection and certification company, has acquired Quay Pharma, a UK based pharmaceutical industry targeted contract development and manufacturing organization (CDMO).

New Fujifilm site will cater to cell culture media market demands in China

07-Dec-2021 By Jane Byrne

Fujifilm Irvine Scientific, Inc, is to build a new bioprocessing center in China, with the goal of ensuring local cell culture media optimization support for vaccines, advanced therapies, and biotherapeutic drug development.

Operations begin at new Genezen lentiviral and retroviral vector lab in Indianapolis

06-Dec-2021 By Jane Byrne

Genezen, a cell and gene therapy focused CDMO, has just opened a new process development and analytical lab, a build that represents the first phase of a 75,000+ square foot cGMP-compliant lentiviral and retroviral vector production facility in Indianapolis.

Speed, flexibility and innovation: Rethinking the way the biopharma industry operates

29-Nov-2021 By Jane Byrne

A new report reveals that “speed-to-market” has jumped up from a lower-ranking business driver before the pandemic to the top priority today for biopharma companies, overtaking cost-based considerations by a healthy margin.

SK investment set to bolster CBM, bring capacity to a ‘starved CGT’ marketplace

25-Nov-2021 By Jane Byrne

Korean company, SK, is investing in the Philadelphia-based Center for Breakthrough Medicines (CBM), a move that will support the US company in its bid to become the world's largest end-to-end cell and gene therapy contract development and manufacturing...

AstraZeneca opens new advanced therapeutics R&D facility in Cambridge

23-Nov-2021 By Jane Byrne

AstraZeneca has built a new R&D facility - The Discovery Centre (DISC) - in Cambridge in the UK.

Emulate enhances tech aimed at supporting disease research and drug development

22-Nov-2021 By Jane Byrne

Emulate, Inc recently launched the Zoë-CM2 Culture Module, a second-generation Zoë instrument core to its ‘Organ-on-a-Chip’ based Human Emulation System.

Increased demand for CDMO microbial outsourcing services

18-Nov-2021 By Jane Byrne

Biotech innovators are looking to CDMOs for their key microbial expertise in order to move their therapies from lab to the market, says Lonza.

Culture riding virtual R&D wave, latest funding round enables development of cloud bioreactors

12-Nov-2021 By Jane Byrne

Culture Biosciences, a company enabling biotech firms to develop and scale manufacturing processes in the cloud, recently announced an $80m Series B round, taking the funds it has raised to date to $100m+.

Special Edition: BioPharma Hubs

Dublin set to get a life sciences incubation and acceleration cluster

10-Nov-2021 By Jane Byrne

A new specialized lab, office and collaboration space for over 100 life science and health technology professionals, entrepreneurs, and researchers was recently announced for The Campus, Cherrywood in South Dublin, Ireland.

Histopathology innovator raises $32m in funding round, looks to accelerate cancer research and drug discovery

09-Nov-2021 By Jane Byrne

HistoWiz, a US-based digital histopathology service company, recently announced the closing of a $32m Series A financing round.

Cutting out the middleman: Waters and Sartorius team up to give scientists direct access to MS data

08-Nov-2021 By Jane Byrne

Waters Corporation and Sartorius are partnering with the aim of providing bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.

Sphere Fluidics closes $40m funding round

05-Nov-2021 By Jane Byrne

Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.

Beyond schizophrenia: The promise of long-acting injectables

27-Oct-2021 By Jane Byrne

Long-acting injectables have huge untapped clinical potential for patients and caregivers, say experts.

Interactive tool shows cost-saving potential of biosimilars in each US state

26-Oct-2021 By Jane Byrne

The Biosimilars Forum, in partnership with the Pacific Research Institute (PRI), recently released a report and interactive tool highlighting the significant costs that biosimilars can save US states.

Waters and University of Delaware in bioprocessing innovation tie-up

25-Oct-2021 By Jane Byrne

Waters has announced a five-year investment to develop new analytical technology for bioprocessing and biomanufacturing with the University of Delaware.

Synthetic biology innovator opens new campus to speed up drug discovery

21-Oct-2021 By Jane Byrne

Absci Corporation says its newly opened campus in Vancouver, Washington, in the US, expands its ability to accelerate discovery and development of biologic drugs.

Charles River and ATEM partner to accelerate drug discovery efforts

19-Oct-2021 By Jane Byrne

Charles River and ATEM Structural Discovery (ATEM) are collaborating to provide access to cryo-electron microscopy (cryo-EM), a technique that visualizes molecules and proteins in atomic resolution to determine their 3D shape.

Autolomous and Vineti align to help cell and gene therapy developers scale-up

19-Oct-2021 By Jane Byrne

Announcing a new partnership, Autolomous and Vineti say they are integrating their technology to ensure scalability when cell and gene therapies become standard of care.

Cyberattacks are vastly more sophisticated and pharma industry is a major target

18-Oct-2021 By Jane Byrne

Pharma and biopharma companies need to reevaluate the measures they are currently taking against ever-evolving cybercrime tactics, says an expert.

Lonza invests in Singapore to support growth in mammalian biologics

11-Oct-2021 By Jane Byrne

Lonza is investing to expand mammalian development services at its Singapore facility; the move will bring additional capacity for cell culture, purification, and analytical services for mammalian biologics.

Absci and EQRx in tie-up to accelerate production of cheaper, protein based therapeutics

06-Oct-2021 By Jane Byrne

Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.

Marken to add Kenya and Ghana to GMP storage network

05-Oct-2021 By Jane Byrne

Marken, the clinical trial logistics subsidiary of UPS Healthcare, is adding significant capacity to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials.

NPD Gallery: Technology Insider

04-Oct-2021 By Jane Byrne

We track some of the more recent developments in biopharma manufacturing tech.

Pharma CEO confidence tops pre-pandemic levels, companies look to nucleic-acid technology assets to fuel growth

30-Sep-2021 By Jane Byrne

CEOs at large pharma and biotech companies are upbeat when it comes to their outlook for both their own company and the industry at large; they also have a healthy appetite for M&A, found a KPMG survey.

Gamma Biosciences invests in Nirrin, looks to address ‘large unmet need’ for accurate real-time in-line analytics

27-Sep-2021 By Jane Byrne

The biopharma industry continues to seek technologies that enable process control, while improving process development times and quality, says a Gamma Biosciences executive.

3i invests in new Switzerland based biologics-focused CDMO

13-Sep-2021 By Jane Byrne

3i Group plc has partnered with a former Lonza executive to create a ‘pure-play, patient-centric and sustainable’ biologics drug product contract development and manufacturing organization (CDMO).

WHO calls for coordinated dementia research efforts, looks to drive innovation in the field

07-Sep-2021 By Jane Byrne

Previously a series of unsuccessful clinical trials for treatments, combined with the high costs of R&D in the area, led to declining interest in dementia research but a new publication from the WHO notes a definite uptick in the funding of such work...

Ardena buys Spain’s Idifarma in move to capitalize on emerging biotech segment

06-Sep-2021 By Jane Byrne

Ardena has acquired Idifarma, a contract manufacturer of niche and highly potent generic and innovative drugs, from Suanfarma; the deal enables it to expand across Southern Europe and supports its strategy to become a leading global CDMO.

Special Edition: Reviewing the advanced therapy pipeline

Maximizing the potency of autologous cell lines: Orgenesis in tie-up with Israeli technology provider

01-Sep-2021 By Jane Byrne

Orgenesis has set up a partnership with Savicell Diagnostics to advance the development, QC testing and manufacturing of its cell and gene therapies.

Vertex boosts cell and genetic therapies toolkit in deal worth up to $1.2bn with Arbor

30-Aug-2021 By Jane Byrne

Boston-based company, Vertex, has signed a deal to use Arbor Biotechnologies’ CRISPR gene-editing technology to develop novel cell therapies for the treatment of serious diseases.

Temperature control, track and trace, global distribution: Cryoport and Mitsubishi set up alliance for Japan and APAC region

26-Aug-2021 By Jane Byrne

Cold chain logistics provider, Cryoport, has established a multi-year strategic partnership with Japan’s Mitsubishi Logistics Corporation (MLC).

Moderna is anchor client in new Azzur on-demand cleanroom facility

18-Aug-2021 By Jane Byrne

Azzur Cleanrooms on Demand (COD) announced this week that it is expanding its ongoing business relationship with Moderna Inc.

Rentschler Biopharma to use Industry 4.0 to transform manufacturing at new Boston site

18-Aug-2021 By Jane Byrne

Earlier this month, Rentschler Biopharma, a contract development and manufacturing organization (CDMO), announced that it had broken ground on its new production facility, adjacent to its existing site in Milford, Massachusetts, in the greater Boston...

Special Edition: Meeting demand for viral vectors

Polyplus launches transfection reagent for large scale viral vector production

18-Aug-2021 By Jane Byrne

Recombinant adeno-associated viruses (rAAVs) are becoming the vector of choice for delivering gene therapies, says the French firm.

Special Edition: Meeting demand for viral vectors

VIVEbiotech looks to overcome challenges related to LVV production

18-Aug-2021 By Jane Byrne

VIVEbiotech, a lentivirus-specialized contract development and manufacturing organization (CDMO) that produces vectors for projects from early-stage to GMP production, is working on enhancing intrinsic lentivirus characteristics and streamlining the process....

US commits $153m to drive innovation in biopharmaceutical manufacturing

05-Aug-2021 By Nick Taylor

The US Department of Commerce has awarded $153m (€130m) to support innovation in biopharma manufacturing.

Biotech Absci sees shares soar in IPO debut

27-Jul-2021 By Jane Byrne

Absci Corp, a Vancouver, Washington headquartered synthetic biology company developing technologies to accelerate drug discovery, has gone public.

New eLearning program aimed at enabling faster clinical adoption and improving patient access to ATMPs

26-Jul-2021 By Jane Byrne

A new UK eLearning program is targeted at healthcare and academic professionals to support their learning on advanced therapy medicinal products (ATMPs).